Aurobindo Pharma ups the ante in oncology space

Aurobindo Pharma, one of the country’s leading drug makers, plans to develop “more than 58 drugs” in the oncology space, besides eight hormone products, and could start regulatory filings for them later this year. Manufacturing of these drugs would commence from 2018-19, the company said in its annual report for 2016-17. 

“The portfolio comprises several products with potential first to file opportunities and 180-day market exclusivities,” the report said.

In the biosimilars space, Aurobindo plans to cash in on the products it acquired through the acquisition of TL Biopharmaceutical AG. The firm will develop, commercialise and market these products globally. The cumulative